Healthcare Services

Global Cancer Tumor Profiling Industry Trends and Market Growth Forecast for 2026–2030

March 30, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Expected For The Cancer Tumor Profiling Market At The End Of The 2026–2030 Forecast Period?

The cancer tumor profiling market has demonstrated rapid expansion in recent years. It is projected to increase from $14.97 billion in 2025 to $17.1 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 14.3%. This historical growth can be linked to several factors including the increased adoption of tumor biopsy testing, the expansion of oncology research programs, the early clinical application of molecular stratification, the proliferation of hospital-based profiling services, and the enhanced availability of sophisticated laboratory infrastructure.

The cancer tumor profiling market is projected to undergo significant expansion in the coming years. It is forecast to achieve a valuation of $28.27 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 13.4%. This projected growth throughout the forecast period stems from factors such as the increasing necessity for precision oncology decision-making, the broadening scope of personalized cancer therapies, rising investments in translational research, the increasing adoption of advanced sequencing technologies, and an elevated focus on predictive oncology diagnostics. Noteworthy trends anticipated during this period include a greater deployment of multi-omics tumor profiling, a surge in the uptake of targeted sequencing panels, the expanding integration of AI-powered biomarker analysis, the wider implementation of personalized treatment planning, and an intensified emphasis on prognostic profiling.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=6053&type=smp

What Drivers Are Shaping The Future Growth Of The Cancer Tumor Profiling Market?

The rising global prevalence of cancer is anticipated to fuel the expansion of the cancer and tumor profiling market in the future. Cancer is characterized by the uncontrolled proliferation and dissemination of certain body cells. With the increasing occurrence of cancer, there is a corresponding surge in the need for cancer tumor profiling, a method used by medical professionals to assess disease progression. For example, in 2024, the American Cancer Society, a US-based professional organization, documented 2 million new cancer diagnoses in the US, an increase from 1.9 million new cases in 2023. Consequently, the growing global incidence of cancer is a key driver for the cancer and tumor profiling market. Cancer Tumor Profiling Market Driver: Growing Incidence Of Stomach Cancer

The escalating occurrence of stomach cancer is set to boost the expansion of the cancer and tumor profiling market in the foreseeable future. Stomach cancer involves the unregulated division and spread of cancerous cells within the stomach’s inner lining. While gastrointestinal stromal tumors (GISTs) can manifest in the stomach, they are a separate condition from stomach cancer. Patients with GISTs have shown a heightened propensity for developing other cancers, such as small bowel adenocarcinoma, when two distinct tumors converge. Cancer and tumor profiling offers crucial data on stomach cancer progression, aiding in more effective treatment strategies. For instance, Cancer Research UK, an independent cancer research body based in the UK, anticipates a 12% reduction in stomach cancer incidence in the UK, dropping to 8 cases per 100,000 people annually on average, between the periods of 2023-2025 and 2038-2040. Consequently, the rising incidence of stomach cancer fuels the growth of the cancer and tumor profiling market.

What Segment Types Make Up The Cancer Tumor Profiling Market?

The cancer tumor profiling market covered in this report is segmented –

1) By Cancer Type: Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Melanoma, Ovarian Cancer, Stomach Cancer, Pancreatic Cancer, Thyroid Cancer, Other Cancer Types

2) By Technology: Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Microarray, Other Technologies

3) By Process Type: Genomics, Proteomics, Epigenetics, Other Types

4) By Application: Personalized Medicine, Diagnostics, Biomarker Discovery, Prognostics, Research Applications

Subsegments:

1) By Lung Cancer: Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC)

2) By Breast Cancer: Hormone Receptor-Positive, Triple-Negative Breast Cancer, HER2-Positive Breast Cancer

3) By Colorectal Cancer: Colon Cancer, Rectal Cancer

4) By Prostate Cancer: Localized Prostate Cancer, Advanced Prostate Cancer

5) By Melanoma: Cutaneous Melanoma, Non-Cutaneous Melanoma

6) By Ovarian Cancer: Epithelial Ovarian Cancer, Non-Epithelial Ovarian Cancer

7) By Stomach Cancer: Gastric Adenocarcinoma, Gastrointestinal Stromal Tumors (GISTs)

8) By Pancreatic Cancer: Exocrine Pancreatic Cancer, Neuroendocrine Tumors

9) By Thyroid Cancer: Papillary Thyroid Cancer, Follicular Thyroid Cancer, Medullary Thyroid Cancer

10) By Other Cancer Types: Kidney Cancer, Bladder Cancer, Liver Cancer, Esophageal Cancer

Who Are The Key Players Driving Competition In The Cancer Tumor Profiling Market?

Major companies operating in the cancer tumor profiling market are F. Hoffmann-La Roche Ltd., Caris Life Sciences, Thermo Fisher Scientific Inc., Illumina Inc., Qiagen, HTG Molecular Diagnostics Inc., NanoString Technologies Inc., NeoGenomics Laboratories Inc., Lucence Health Inc., ACT Genomics Co. LTD, Strand Life Sciences, Exact Sciences Corporation, Guardant Health, Foundation Medicine Inc., Agilent Technologies Inc., Myriad Genetics Inc., Personal Genome Diagnostics Inc., Tempus Labs Inc., ArcherDX Inc., Natera Inc., Bio-Rad Laboratories Inc., Genetron Health, NantHealth Inc., Resolution Bioscience, OncoDNA, Strata Oncology Inc., RareCyte Inc., Inivata Limited, Cepheid

Read the full cancer tumor profiling market report here:

https://www.thebusinessresearchcompany.com/report/cancer-tumor-profiling-global-market-report

Which Geographic Regions Are Influencing Demand In The Cancer Tumor Profiling Market?

North America was the largest region in cancer and tumor profiling market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer tumor profiling market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Cancer Tumor Profiling Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=6053&type=smp

Browse Through More Reports Similar to the Global Cancer Tumor Profiling Market 2026, By The Business Research Company

Community Oncology Services Global Market Report

https://www.thebusinessresearchcompany.com/report/community-oncology-services-global-market-report

Oncology Drugs Market

https://www.thebusinessresearchcompany.com/report/oncology-drugs-market

Cancer Supportive Care Drugs Global Market Report

https://www.thebusinessresearchcompany.com/report/cancer-supportive-care-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795